Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

DOI: https://doi.org/10.1177/24755303231195882

Abstract:[This corrects the article DOI: 10.1177/24755303221077211.].

What problem does this paper attempt to address?

Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

DOI: https://doi.org/10.1177/24755303231195871

Abstract:[This corrects the article DOI: 10.1177/2475530320910466.].
Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

DOI: https://doi.org/10.1177/24755303231195857

Abstract:[This corrects the article DOI: 10.1177/2475530321995516.].
Corrigendum to “Exploring comorbidity and pharmacological treatment patterns in psoriasis - A retrospective population-based cross-sectional study”

DOI: https://doi.org/10.1177/26335565231223601

2023-12-01

Journal of Multimorbidity and Comorbidity

Abstract:[This corrects the article DOI: 10.1177/26335565231212336.].
Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

DOI: https://doi.org/10.1177/24755303231195883

Abstract:[This corrects the article DOI: 10.1177/24755303211037308.].
Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

DOI: https://doi.org/10.1177/24755303231195864

Abstract:[This corrects the article DOI: 10.1177/2475530320925067.].
Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series

DOI: https://doi.org/10.1177/24755303231195862

Abstract:[This corrects the article DOI: 10.1177/2475530320970538.].
Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

DOI: https://doi.org/10.1177/24755303231195884

Abstract:[This corrects the article DOI: 10.1177/24755303211029598.].
Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Alexander Egeberg,Joseph F. Merola,Knut Schäkel,Luis Puig,Patrick D. Mahar,Isabella Yali Wang,Imre Pavo,Christopher Schuster,Christopher E. M. Griffiths

DOI: https://doi.org/10.3389/fmed.2023.1171132

IF: 3.9

2023-03-10

Frontiers in Medicine

Abstract:[This corrects the article DOI: 10.3389/fmed.2022.1092688.].

medicine, general & internal
Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis

DOI: https://doi.org/10.1177/24755303231195863

Abstract:[This corrects the article DOI: 10.1177/2475530320970530.].
Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities

DOI: https://doi.org/10.1177/24755303231195867

Abstract:[This corrects the article DOI: 10.1177/24755303221131257.].
Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis

DOI: https://doi.org/10.1177/24755303231195869

Abstract:[This corrects the article DOI: 10.1177/2475530320950265.].
Corrigendum to Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey

DOI: https://doi.org/10.1177/24755303231195873

Abstract:[This corrects the article DOI: 10.1177/24755303211067822.].
Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis

DOI: https://doi.org/10.1177/24755303231195868

Abstract:[This corrects the article DOI: 10.1177/24755303211051724.].
Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

C. A. M. van Riel,C. A. J. Michielsens,M. E. van Muijen,L. S. van der Schoot,J. M. P. A. van den Reek,E. M. G. J. de Jong

DOI: https://doi.org/10.3389/fphar.2024.1505626

IF: 5.6

2024-10-15

Frontiers in Pharmacology

Abstract:This article is a correction to: Dose reduction of biologics in patients with plaque psoriasis: a review

pharmacology & pharmacy
Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

DOI: https://doi.org/10.1177/24755303231195874

Abstract:[This corrects the article DOI: 10.1177/24755303211056059.].
Corrigendum to Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey

DOI: https://doi.org/10.1177/24755303231195870

Abstract:[This corrects the article DOI: 10.1177/2475530320956602.].
Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report

DOI: https://doi.org/10.1177/24755303231196711

Abstract:[This corrects the article DOI: 10.1177/2475530320950290.].
Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring

DOI: https://doi.org/10.1177/24755303231195872

Abstract:[This corrects the article DOI: 10.1177/24755303211011477.].
Erratum: Asymptomatic Erythematous and Tan, Shiny, Well-Defined Plaques: Erratum

DOI: https://doi.org/10.1097/JW9.0000000000000050

2022-09-02

Abstract:[This corrects the article DOI: 10.1097/JW9.0000000000000029.].
Correction to Lancet Rheumatol 2020; 2: e557-64

DOI: https://doi.org/10.1016/S2665-9913(21)00137-5

Abstract:[This corrects the article DOI: 10.1016/S2665-9913(20)30227-7.].

Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data

Corrigendum to Dosage Adjustments in Patients With Psoriasis on Etanercept: A Retrospective Chart Review

Corrigendum to Tofacitinib for the Treatment of Refractory Palmoplantar Psoriasis: A Case Series

Corrigendum to “Exploring comorbidity and pharmacological treatment patterns in psoriasis - A retrospective population-based cross-sectional study”

Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series

Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series

Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis

Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities

Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis

Corrigendum to Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey

Corrigendum to Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis

Corrigendum: Dose reduction of biologics in patients with plaque psoriasis: a review

Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients

Corrigendum to Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey

Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report

Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring

Erratum: Asymptomatic Erythematous and Tan, Shiny, Well-Defined Plaques: Erratum

Correction to Lancet Rheumatol 2020; 2: e557-64